Abbott Kicks Off Transcatheter Tricuspid Repair Device Trial
Abbott has enrolled the first patient in a clinical trial for its minimally-invasive transcatheter valve repair system.
The patient, enrolled at the Abbott Northwestern Hospital, will aid in assessment of the transcatheter system, which is used to treat heart patients with severe tricuspid regurgitation, the leakage of blood backward through the tricuspid valve. The company is seeking CE Mark approval in the European Union for the device.
The system derives from clip-based technology the company has already tested with its MitraClip system for mitral valve regurgitation.